Amber Salzman.png

Amber Salzman, Ph.D.
President and CEO

Dr. Salzman is the President and CEO of Ohana Biosciences. She previously served as the President and CEO at Adverum Biotechnologies, and was a Co-Founder of Annapurna Therapeutics SAS where she served as its President and CEO prior to its merger with Avalanche Biosciences to create Adverum Biotechnologies.

Prior to her role at Adverum Biotechnologies, Dr. Salzman served as President and CEO of Cardiokine, Inc. until it was acquired by Cornerstone Therapeutics. Prior to that, she was a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for Operations for Medicine Development across therapeutic areas, planning and managing drug development projects and clinical trials with over 30,000 active patients around the world.

In addition to her roles in industry, Dr. Salzman is the President of the Stop ALD Foundation, a Medical Research Foundation dedicated to finding better therapies for people with adrenoleukodystrophy and advocating on behalf of patients with rare diseases. She was instrumental in establishing the first gene therapy human proof of concept for ALD and adding ALD to the national recommended list of diseases for which newborns should be screened.

Additionally, she serves on the Boards of Lankenau Institute of Medical Research and Drexel University Dornsife School of Public Health.

Dr. Salzman received her Bachelor's degree from Temple University and holds a Ph.D. in Mathematics from Bryn Mawr College. Honors include being inducted into Temple University's League of Entrepreneurial Women Hall of Fame.

Lance Colwell.png

Lance Colwell, B.S.
Chief Operating Officer

Mr. Colwell joined Ohana Biosciences assuming the newly created position of Chief Operating Officer to lead a range of functions, including Program and Portfolio Management, Technical Operations, Medical Affairs, Corporate Affairs, and Business Development.

Mr. Colwell is a proven global pharmaceutical executive with a nearly 30-year track record of consistently delivering sustainable growth through multiple business cycles. He joined Ohana from Biogen, where he was the Vice President of the Rare Disease Group and responsible for the successful launch of SPINRAZA in the U.S. During his 14-year tenure at Biogen, Mr. Colwell led or supported multiple drug launches and held a range of leadership roles, including VP of Global Commercial Excellence and Operations, Austrian Country Head, Global Head of Medical Affairs Operations, Head of Commercial Training and Development, and a variety of marketing/brand leadership responsibilities for TYSABRI, AVONEX, MS Franchise, and German Affiliate Marketing.

Prior to Biogen, Mr. Colwell led, or was involved with, several commercial launches via sales or marketing while working for Purdue Pharma, Bayer, Searle, and Carter Wallace. He has experience in over 20 different therapeutic areas across rare disease, specialty and mass markets.

Mr. Colwell received his B.S. in Marketing from Bentley University.

Eric Furfine.png

Eric Furfine, Ph.D.
Chief Scientific Officer

Dr. Furfine joined Ohana Biosciences as Chief Scientific Officer. Previously, Dr. Furfine was at Eleven Biotherapeutics, where his roles included Chief Scientific Officer and President of Research and Development, and where he led the discovery and early development of EBI-031, an IL-6 inhibitory antibody for the treatment of posterior ocular inflammatory diseases. Dr. Furfine currently serves on the scientific advisory boards of Mosaic Biosciences and OH2 Laboratories.

Prior to Eleven Biotherapeutics, Dr. Furfine served as the Senior Vice President of Research and Preclinical Development of Adnexus Therapeutics, Inc., a Bristol-Myers Squibb research and development company, where his group discovered Adnectins, which advanced into clinical development. Prior to that, he was Vice President of Preclinical Development at Regeneron, where he led the non-clinical development and clinical pharmacology of ARCALYST, EYLEA, and ZALTRAP. Dr. Furfine began his career in the pharmaceutical industry at Burroughs Welcome, which became GlaxoSmithKline, where he was the inventor of LEXIVA.

Dr. Furfine received a A.B. in Chemistry from Washington University in St. Louis, a Ph.D. from Brandeis University in Biochemistry, and did postdoctoral research in molecular parasitology at the University of California, San Francisco, CA.

Caren Deardorf.png

Caren B. Deardorf, B.S., MBA
Chief Commercial Officer

Ms. Deardorf joined Ohana as Chief Commercial Officer to lead the building of a commercial organization and capabilities, thereby bringing Ohana’s pipeline of products to patients.

Prior to joining Ohana, Ms. Deardorf was at Biogen, where she was Vice President and Global Lead for SPINRAZA and the SMA Portfolio. In her role at Biogen, she led the global launch of SPINRAZA in over 40 countries, overseeing the regulatory, market access and commercial launch planning and execution.

Over the course of her career at Biogen, Ms. Deardorf played key roles as Global and U.S. Brand Lead for several of the important MS products (AVONEX, TYSABRI, and TECFIDERA) that have helped thousands of patients around the world. She lived in France to launch AVONEX across Europe.

Ms. Deardorf is a member of the board of directors for the Pan Mass Challenge, which raises critical funds for the Dana Farber Cancer Institute, and serves on the board of directors of the MacJannet Foundation, which supports international exchange and education. 

Ms. Deardorf received her B.S. in Biology from Tufts University and her MBA from the Olin School of Management, Babson College.  

Dave McManus.png

David McManus, B.B.A., C.P.A.
Vice President of Finance, Treasurer and Secretary

Mr. McManus joined Ohana Biosciences as Vice President of Finance, Treasurer and Secretary, and leads all aspects of the company’s Finance and Accounting, IT, and Facilities Operations. Over his career, he has raised nearly $100 million of equity and debt financing across multiple companies at various stages of growth and has played a significant role in leading two companies through successful acquisitions.

Prior to joining Ohana, Mr. McManus was Executive Director and Corporate Controller at Good Start Genetics, a commercial-stage provider of clinically-advanced genetic testing in reproductive health. At Good Start, he built and led various financial and operational functions over 7+ years, from pre-commercial stage to commercial launch and accelerated growth, through company turnaround and successful acquisition by Invitae in 2017. Previously, Mr. McManus was Controller at VisEn Medical, a Flagship Pioneering company that developed and commercialized transformative in vivo molecular imaging systems and reagents for cancer, cardiovascular, skeletal, and pulmonary applications.  At VisEn, he was part of the leadership team that executed on record commercial growth and the acquisition of the company by PerkinElmer, Inc. in 2010.

Prior to VisEn, Mr. McManus was an Audit Manager at Sullivan Bille, PC (2001-2008), where he led financial statement audits of privately-held companies primarily in manufacturing and biotech/life sciences industries.

Mr. McManus received a Bachelor’s degree in Business Administration, Accounting from the University of Massachusetts, Lowell and obtained his C.P.A. license shortly thereafter.